Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review
(2022)
Journal Article
Papapetropoulos, A., Topouzis, S., Alexander, S. P. H., Cortese‐Krott, M., Kendall, D. A., Martemyanov, K. A., …Ferdinandy, P. (2022). Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review. British Journal of Pharmacology, https://doi.org/10.1111/bph.16337
In 2023, seventy novel drugs received market authorization for the first time in either Europe (by the EMA and the MHRA) or in the United States (by the FDA). Confirming a steady recent trend, more than half of these drugs target rare diseases or int... Read More about Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review.